Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Neuronetics (STIM) over the last 9 years, with Q3 2025 value amounting to -$2000.0.

  • Neuronetics' Gains from Investment Securities fell 10012.55% to -$2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $194000.0, marking a year-over-year decrease of 8782.17%. This contributed to the annual value of $1.2 million for FY2024, which is 259.84% down from last year.
  • Latest data reveals that Neuronetics reported Gains from Investment Securities of -$2000.0 as of Q3 2025, which was down 10012.55% from $4.1 million recorded in Q1 2025.
  • Neuronetics' Gains from Investment Securities' 5-year high stood at $6.5 million during Q1 2021, with a 5-year trough of -$2000.0 in Q3 2025.
  • Its 5-year average for Gains from Investment Securities is $1.4 million, with a median of $1.3 million in 2023.
  • In the last 5 years, Neuronetics' Gains from Investment Securities surged by 3217500.0% in 2023 and then tumbled by 10012.55% in 2025.
  • Neuronetics' Gains from Investment Securities (Quarter) stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then skyrocketed by 1170.0% to $1.3 million in 2023, then decreased by 2.6% to $1.2 million in 2024, then crashed by 100.16% to -$2000.0 in 2025.
  • Its Gains from Investment Securities stands at -$2000.0 for Q3 2025, versus $4.1 million for Q1 2025 and $1.2 million for Q4 2024.